pharma

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Shares Up on Stronger than Expected Q4 Beat

AbbVie Inc. (NYSE: ABBV) reported its fourth quarter financial results for fiscal year 2017. The pharmaceutical company reported better than expected earnings sending shares 13.5 percent before market close on Friday.For the fourth quarter, AbbVie r..

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Misses Earnings but Tops Revenue Estimates

Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter financial results for fiscal year 2017. The U.S. drug-maker fell short on earnings estimates, but topped revenue estimates, sending shares 3 percent higher during Thursday’s pre-marke..

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..

Teva Pharmaceuticals to Cut 25% of Jobs

Teva Pharmaceuticals to Cut 25% of Jobs

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), based in Israel, is one of the world’s largest makers of generic drugs. The pharmaceutical giant has had a rough year, facing declining prices for generic drugs and the loss of a major branded d..

Teva May Cut 10,000 Jobs

Teva May Cut 10,000 Jobs

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced the cut of 10,000 jobs as the company aims to reduce $1.5 billion to $2 billion in costs over the next two years. Following this announcement, the drug maker’s U.S. shares increase..

CVS-Aetna Merger and Healthcare Clinics' Future

CVS-Aetna Merger and Healthcare Clinics' Future

While investors were pitched the multiple benefits of the $69 billion CVS Health Corp (NYSE: CVS) - Aetna Inc (NYSE: AET) merger, the former pitched to its shareholders and the general public that this merger could transform the drugstores owned by ..

Regeneron Pharma beats Q3 earnings

Regeneron Pharma beats Q3 earnings

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third quarter earnings for fiscal year 2017 and beat analysts’ estimates, sending shares up almost 7 percent shortly after open on Wednesday.For the third quarter, Regeneron reported r..